Condition

Chronic Lymphocytic Leukemia (CLL) (7)

Small Lymphocytic Lymphoma (SLL) (2)

Adult T-Cell Leukemia/Lymphoma (ATLL) (1)

Cutaneous T-cell Lymphoma (CTCL) (1)

Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype (1)

Mycosis Fungoides (MF) (1)

Overall Status

Completed (3)

Approved for marketing (1)

Recruiting (1)

Terminated (1)

Withdrawn (1)

Phase

phase 2 (4)

phase 1 (2)

Sponsor

Gilead Sciences (2)

AbbVie (1)

Genzyme, a Sanofi Company (1)

MedImmune LLC (1)

University of California, San Diego (1)

miRagen Therapeutics, Inc. (1)

Collaborator

Celgene Corporation (1)

F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute (1)

Intervention

rituximab (3)

idelalisib (2)

bendamustine (1)

cobomarsen (1)

lenalidomide (1)

medi-551 (1)

obinutuzumab (1)

plerixafor (1)

venetoclax (1)

Study Documents

Intervention Type

drug (7)

Funder Type

Industry (6)

Other (1)

Study Type

Interventional (6)

Expanded Access (1)

Chronic Lymphocytic Leukemia (CLL)

Showing NaN - NaN of 7

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED